Ovid Therapeutics
Stock Forecast, Prediction & Price Target
Ovid Therapeutics Financial Estimates
Ovid Therapeutics Revenue Estimates
Ovid Therapeutics EBITDA Estimates
Ovid Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $208.38M N/A | $1.50M -99.27% | $391.69K -73.93% | Avg: $37.67M Low: $2.08M High: $73.27M avg. 9519.57% | Avg: $6.9M Low: $478.64K High: $13.37M avg. -81.68% | Avg: $48.84M Low: $3.38M High: $94.66M avg. 607.82% | Avg: $65.45M Low: $4.54M High: $126.86M avg. 34.02% |
Net Income
% change YoY
| $122.83M N/A | $-51.40M -141.85% | $-52.33M -1.81% | Avg: $-47.68M Low: $-55.05M High: $10.58M avg. 8.88% | Avg: $-67.74M Low: $-48.70M High: $-29.64M avg. -42.05% | Avg: $-39.87M Low: $-88.51M High: $8.36M avg. 41.13% | Avg: $-20.64M Low: $-45.82M High: $4.33M avg. 48.23% |
EBITDA
% change YoY
| $124.44M N/A | $-55.54M -144.63% | $-58.71M -5.69% | Avg: $-10.57M Low: $-20.55M High: $-584.30K avg. 81.99% | Avg: $-1.93M Low: $-3.75M High: $-134.28K avg. 81.68% | Avg: $-13.70M Low: $-26.55M High: $-950.51K avg. -607.82% | Avg: $-18.36M Low: $-35.59M High: $-1.27M avg. -34.02% |
EPS
% change YoY
| $1.78 N/A | -$0.73 -141.01% | -$0.74 -1.36% | Avg: -$0.54 Low: -$0.78 High: $0.15 avg. 27.02% | Avg: -$0.6 Low: -$0.69 High: -$0.42 avg. -11.57% | Avg: -$0.57 Low: -$1.25 High: $0.12 avg. 6.22% | Avg: -$0.29 Low: -$0.65 High: $0.06 avg. 48.23% |
Operating Expenses
% change YoY
| $84.17M N/A | $57.05M -32.22% | $59.67M 4.59% | Avg: $765.22M Low: $42.29M High: $1.48B avg. 1182.36% | Avg: $140.13M Low: $9.72M High: $271.60M avg. -81.68% | Avg: $991.88M Low: $68.80M High: $1.92B avg. 607.82% | Avg: $1.32B Low: $92.21M High: $2.57B avg. 34.02% |
FAQ
What is Ovid Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.04% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -55.05M, average is -47.68M and high is 10.58M.
What is Ovid Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2519.93% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $2.08M, average is $37.67M and high is $73.27M.
What is Ovid Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 17.47% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$0.78, average is -$0.54 and high is $0.15.
What is the best performing analyst?
In the last twelve months analysts have been covering Ovid Therapeutics stock. The most successful analyst is Raghuram Selvaraju.